Bristol signs new deal with Five Prime involving CSFR1 antibody
Executive Summary
Replacing a deal signed in March 2014, Bristol-Myers Squibb Co. received exclusive global rights to develop and sell Five Prime Therapeutics Inc.'s Phase I colony stimulating Factor 1 receptor (CSF1R) inhibitor antibody FPA008 (cabiralizumab) for immuno-oncology indications. The agreement also includes all modifications, derivatives, fragments or variants of anti-CSFR1 antibodies.
Deal Industry
- Pharmaceuticals
-
Biotechnology
- Immuno-Oncology
-
Large Molecule
- Antibodies
Deal Status
- Final
Deal Type
-
Alliance
- Co-Promotion
- Includes Royalty or Profit Split Information
- R&D and Marketing (Licensing)
- Trial Collaborations
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice